Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
Fish and Richardson
US Army
Cantor Fitzgerald
Medtronic

Generated: May 19, 2019

DrugPatentWatch Database Preview

XOLAIR Drug Profile

« Back to Dashboard

Summary for Tradename: XOLAIR
Patents:95
Applicants:1
BLAs:1
Suppliers: see list1
Pharmacology for XOLAIR
Mechanism of ActionIgE-directed Antibody Interactions
Physiological EffectDecreased IgE Activity

US Patents for XOLAIR

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20 ➤ Try a Free Trial LegoChem Biosciences, Inc. (Daejeon, KR) ➤ Try a Free Trial RX search
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20 ➤ Try a Free Trial BIONANOPLUS, S.L. (Noain-Navarra, ES) ➤ Try a Free Trial RX search
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20 ➤ Try a Free Trial ATOPIX THERAPEUTICS LIMITED (London, GB) ➤ Try a Free Trial RX search
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20 ➤ Try a Free Trial SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) ➤ Try a Free Trial RX search
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20 ➤ Try a Free Trial LegoChem Biosciences, Inc. (Daejeon, KR) ➤ Try a Free Trial RX search
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20 ➤ Try a Free Trial Banner Life Sciences LLC (High Point, NC) ➤ Try a Free Trial RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for XOLAIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
92780 Luxembourg ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
93138 Luxembourg ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
CA 2015 00043 Denmark ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
CR 2016 00031 Denmark ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
122016000049 Germany ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
PA2016022 Lithuania ➤ Try a Free Trial PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Teva
Chubb
Medtronic
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.